This independent medical education activity features an expert interview with Anders Österborg, MD, PhD, and William G. Wierda, MD, PhD, focusing on important data from a recent publication reporting on the results of a phase II trial of ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) with or without previous exposure to rituximab. (Wierda WG, et al. Blood. 2011;118(19):5126-5129).

This Webcast is available from 13 February 2012 to 13 February 2013.

Expert perspectives with Gregory Cheng, MD, PhD, and Aristoteles Giagounidis, MD, PhD, regarding the use of eltrombopag for the management of chronic immune thrombocytopenia.
This Webcast is available from 23 February 2011 to 23 February 2012.

Expert perspectives with Michele Baccarani, MD, and Jorge Cortes, MD, regarding the use of nilotinib in patients with chronic phase chronic myelogenous leukemia following imatinib resistance or intolerance.
This Webcast is available from 12 January 2011 to 12 January 2012.

Expert perspectives with Irene Ghobrial, MD, and Aristoteles Giagounidis, MD, PhD, regarding the use of everolimus for the management of relapsed or refractory Waldenström macroglobulinemia.
This Webcast is available from 11 January 2011 to 11 January 2012.

Expert perspectives with Anders Österborg, MD, PhD, and Aristoteles Giagounidis, MD, PhD, regarding ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
This Webcast is available from 17 September 2010 to 17 September 2011.

Expert perspectives with Neil Shah, MD, PhD, and Michael Deininger, MD, PhD, regarding dasatinib 100 mg once daily as second-line therapy in chronic-phase chronic myeloid leukemia
This Webcast is available from 7 September 2010 to 7 September 2011.